Jaguar Health, Inc. (NASDAQ:JAGX)

PRESS RELEASE

published on 06/23/2025 at 15:00, 1 year ago

Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer
Enrollment in Jaguar Health's placebo-controlled Phase 2 study for microvillus inclusion disease (MVID) reaches 25%. Crofelemer shows promise in reducing total parenteral nutrition in pediatric patients with MVID and short bowel syndrome, seeking business partnerships for non-dilutive funding

Crofelemer Jaguar Health Phase 2 Study MVID Intestinal Failure
BRIEF

published on 06/17/2025 at 15:05, 1 year ago

Jaguar Health participera à la conférence Emerging Growth

Napo Pharmaceuticals Crofelemer Jaguar Health Lisa Conte Conférence Sur La Croissance Émergente
BRIEF

published on 06/17/2025 at 15:05, 1 year ago

Jaguar Health to Present at Emerging Growth Conference

Napo Pharmaceuticals Crofelemer Jaguar Health Lisa Conte Emerging Growth Conference
PRESS RELEASE

published on 06/17/2025 at 15:00, 1 year ago

Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts
Jaguar Health, Inc. to present virtually at Emerging Growth Conference on June 18, 2025. Focus on pharmaceuticals from rainforest plants for gastrointestinal distress. Notable brands: Mytesi, Napo Therapeutics

Pharmaceuticals Gastrointestinal Distress Jaguar Health Emerging Growth Conference Mytesi
BRIEF

published on 06/11/2025 at 16:05, 1 year ago

Jaguar Health lance une étude sur le médicament Canalevia-CA1 chez le chien

Crofelemer Jaguar Health Canalevia-CA1 Approbation De La FDA Diarrhée Du Chien
BRIEF

published on 06/11/2025 at 16:05, 1 year ago

Jaguar Health Launches Study for Canalevia-CA1 Drug in Dogs

Crofelemer FDA Approval Jaguar Health Canalevia-CA1 Dog Diarrhea
PRESS RELEASE

published on 06/11/2025 at 16:00, 1 year ago

First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs
Jaguar Health, Inc. announces goals to expand crofelemer usage from chemotherapy-induced to general diarrhea treatment in dogs. Research studies and partnerships in progress

Crofelemer Jaguar Health Partnerships Dogs Diarrhea Treatment
BRIEF

published on 06/09/2025 at 22:20, 1 year ago

Jaguar Health discutera des résultats de l'essai de phase 3 lors d'une discussion virtuelle

Jaguar Health Essai De Phase 3 Cancer Du Sein Maladies Orphelines Réunion De La FDA
BRIEF

published on 06/09/2025 at 22:20, 1 year ago

Jaguar Health to Discuss Phase 3 Trial Results in Virtual Chat

Jaguar Health Phase 3 Trial Breast Cancer Orphan Diseases FDA Meeting
PRESS RELEASE

published on 06/09/2025 at 22:15, 1 year ago

REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series
Jaguar Health, Inc. to discuss Phase 3 OnTarget trial results for metastatic breast cancer subgroup. Focus on orphan population and expanded access program. Virtual fireside chat with CEO Lisa Conte on June 10, 2025

Jaguar Health Phase 3 OnTarget Trial Virtual Fireside Chat Metastatic Breast Cancer Orphan Population

Published on 06/26/2026 at 15:05, 3 hours 57 minutes ago

Vox Royalty Sells I-80 Gold Offtake Stream
Published on 06/26/2026 at 14:05, 4 hours 57 minutes ago

SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 14:00, 5 hours 2 minutes ago

Dateline Chairman Invests $1.95 million through Options Exercise
Published on 06/26/2026 at 13:00, 6 hours 2 minutes ago

Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 12:45, 6 hours 17 minutes ago

Northern Dynasty Reports Oral Arguments Held

View all ACCESSWIRE

Published on 06/26/2026 at 18:04, 57 minutes ago

Turkiye Garanti Bankasi A.S.: Bond, subordinated debts, that can be included in the equity calculation debt instrument issuance CMB Application
Published on 06/26/2026 at 18:00, 1 hour 1 minute ago

PSP Swiss Property has sold the Richtipark in Wallisellen. The EBITDA guidance for the 2026 financial year has been increased.
Published on 06/26/2026 at 18:00, 1 hour 1 minute ago

VALBIOTIS SA: Valbiotis announces the success of its capital increase of €10.2M
Published on 06/26/2026 at 18:00, 1 hour 1 minute ago

VALBIOTIS SA: Valbiotis annonce le succès de son augmentation de capital de 10,2 M€ entièrement dédiée à soutenir l’expansion commerciale de son offre de produits de santé naturels
Published on 06/26/2026 at 18:00, 1 hour 1 minute ago

ROCTOOL: Summary of the Roctool Annual General Meeting held on June 26, 2026

View all EQS

Published on 06/26/2026 at 17:45, 1 hour 17 minutes ago

Combined General Meeting, June 25, 2026
Published on 06/26/2026 at 17:45, 1 hour 17 minutes ago

Assemblée générale mixte du 25 juin 2026
Published on 06/26/2026 at 17:45, 1 hour 17 minutes ago

Descriptif du programme de rachat d'actions
Published on 06/26/2026 at 14:44, 4 hours 17 minutes ago

Safran information
Published on 06/26/2026 at 14:44, 4 hours 17 minutes ago

Information Safran

View all LES ECHOS COMFI WIRE

News